Clinical trials: Melasma
Melasma
A Clinical Study to Evaluate the Effect of Facial Serum Q69 in Moderating the Appearance of Mild to Moderate Melasma
This is a single centre, 2-cell, single blinded full-face (products applied at lesional sites) study to evaluate changes in melasma through a cosmetic facial serum formulation and marketed 2% Hydroquinone product
- Trial name
- NCT05013801
- Testing
- Cosmetic facial serum Q69, 2% Hydroquinone
- Where
- China
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Unilever R&D
Refractory Melasma
Fractional Erbium YAG Laser vs Intradermal and Systemic Tranexamic Acid
Melasma is a common acquired disorder of hyperpigmentaion caused by increased melanin production by melanocytes. Melasma is a name derived from the Greek word melas meaning black.It is characterized by the appearance of brownish…
- Trial name
- NCT06522984
- Testing
- Tranexamic acid injection
- Where
- Egypt
- Volunteers
- 45 people
- Sponsor
- Egymedicalpedia
Melasma
Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Participants With Moderate Facial Melasma
The objective of this study is to evaluate the efficacy and tolerability of Lytera 2.0 versus 4% hydroquinone in the improvement of the appearance of moderate facial melasma.
- Trial name
- NCT02977507
- Testing
- Lytera 2.0, 4% Hydroquinone Topical Cream, SkinMedica Facial Cleanser
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Allergan
Melasma
A Study of the RevLite Laser System for the Treatment of Refractory Mixed Type Melasma
The purpose of this study is to compare a hydroquinone skin care regimen alone to a combination of Revlite Laser treatment with a hydroquinone skin care regimen for the treatment of melasma.
- Trial name
- NCT02110134
- Testing
- Revlite Laser System with hydroquinone skin care regimen, Hydroquinone skin care regimen
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Cynosure, Inc.
Chloasma
Identification of Biomarkers and Characterization of Melasma
Melasma (also called chloasma and pregnancy mask) is characterized by pigmented lesions darker than their usual complexion on the faces of affected subjects. The physiopathology of melasma is still poorly understood.
- Trial name
- NCT03618277
- Testing
- Biopsy
- Sponsor
- Pierre Fabre Dermo Cosmetique
Melasma
Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma
To determine the effectiveness and safety of sequential therapy with of Tri-Luma® Cream and a series of Glycolic Acid peels in treatment of moderate to severe melasma.
- Trial name
- NCT00472966
- Testing
- Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Galderma R&D
Melasma
Melanil in the Treatment of Melasma
The purpose of the study is to assess the efficacy of Melanil facial cream in the treatment of melasma. The duration of this double-blind phase 3 clinical trial will be 54 weeks.
- Trial name
- NCT01001624
- Testing
- Melanil facial cream, Hydroquinone 2% cream
- Where
- Cuba
- Volunteers
- 150 people
- Sponsor
- Catalysis SL
Hyperpigmentation
Efficacy and Tolerability of Tested Formula After 3 Months in Treatment of Facial Hyperpigmentation of 3 Origins
The objective of this study is to evaluate the efficacy, cosmetic acceptability and improvement of the stigmatization of the tested product (2039125 03) used bis in die (BID) for 3 months in adult patients suffering from mild to…
- Trial name
- NCT06320314
- Testing
- tested product (2039125 03)
- Where
- Portugal
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Melasma
Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma
Evaluate atrophogenic potential of long-term use of Tri-Luma Cream on facial Melasma through biopsy examination.
- Trial name
- NCT00469183
- Testing
- Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05%
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- Galderma R&D
Melasma, Lentigines
A Prospective Multi-Center Study Using Laser for the Treatment of Melasma and Lentigines in Asian Skin
The purpose of this investigation is to evaluate safety and efficacy of the Cutera enlighten dual-pulse duration, dual-wavelength 532nm KTP/1064nm Nd:YAG laser for the treatment of melasma and lentigines on the face in Asian skin.
- Trial name
- NCT02385994
- Testing
- enLighten Laser
- Where
- 2 sites in China, Japan
- Volunteers
- 80 people
- Sponsor
- Cutera Inc.
Melasma
Revlite Laser System Compared to the Candela Alex TriVantage System Refractory Mixed Type Melasma
This proof of concept study will be conducted to assess the aesthetic improvement in refractory mixed type melasma in subjects treated with two FDA 510K approved devices: Q Switched Nd: YAG Laser vs. Alex TriVantage
- Trial name
- NCT01745224
- Testing
- Revlite Q switched Nd:YAG, Trivantage Q switched Nd: YAG
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Cynosure, Inc.
Healthy
A Study to Assess Effect of Two Facial Sunscreens in Improving Wrinkles, Fine Lines and Melasma in Adult Participants
The purpose of this study is to evaluate the topical safety (tolerability/acceptability) and efficacy of two facial sunscreen in improving wrinkles, fine lines and melasma after 84 +/- 2 days of use under normal conditions on the…
- Trial name
- NCT05864417
- Testing
- Sunscreen Color tone 2.0, Sunscreen Color tone 3.0
- Where
- Brazil
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Refractory Mixed Type Melasma
Study of Laser Treatment of Melasma
The purpose of this study is to evaluate the RevLite laser in the treatment of refractory mixed type melasma.
- Trial name
- NCT01335581
- Testing
- Q-Switched Nd:YAG Laser (RevLite), Retin-A and microdermabrasion
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- ConBio, a Cynosure Company
Post-inflammatory Hyperpigmentation, Melasma
A Clinical Study to Evaluate the Efficacy in Improving Dark Spots After 8 Weeks of Use of Facial Sunscreens in Adult Participants
The study aims to evaluate the efficacy of a facial sunscreen under two experimental conditions-untinted and tinted-in improving facial spots (melasma and solar lentigines/post-inflammatory hyperpigmentation) after 8 weeks of…
- Conditions
- Post-inflammatory Hyperpigmentation, Melasma, Solar Lentigo
- Trial name
- El Porto Ex-US (NCT07679945)
- Testing
- Sunscreen untinted, Sunscreen tinted
- Where
- Brazil
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Kenvue Brands LLC
Healthy, Melasma (Facial Melasma)
COMPARISON OF A COSMETIC SERUM AND 4% HYDROQUINONE FOR TREATING MELASMA OVER 84 DAYS
The goal of this clinical trial is to compare the dermatological tolerance and skin-lightening efficacy of a cosmetic depigmenting serum to a 4% hydroquinone-based product in adult male and female subjects aged 18-65 years with…
- Conditions
- Healthy, Melasma (Facial Melasma), Epidermal Melasma
- Trial name
- NCT07071363
- Testing
- Depigmenting Cosmetic Serum (Applied Morning and Evening)
- Where
- Mauritius
- Volunteers
- 40 people
- Sponsor
- Laboratoire Dermatologique ACM
Hyperpigmentation, Melasma
Evaluation of Efficacy and Tolerabilty of MelaB3 Serum in Combination of 35% Glycolic Acid Peeling Compared to 35% Glycolic Acid Peeling Alone in Various Hyperpigmentation Conditions
Randomized clinical trial to assess the effectiveness and tolerability of Mela B3 serum in combination with 35% glycolic acid peel vs.
- Conditions
- Hyperpigmentation, Melasma, Solar Lentigo, Peeling
- Trial name
- NCT07429786
- Testing
- Glycolic acid peel alone, MelaB3 serum
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Melasma
Efficacy and Safety of Picosecond, Neodymium-doped Yttrium Aluminum Garnet Laser Therapy Using 1,064 nm and 595 nm
This is a prospective, multi-center, split-face, controlled clinical trial that aims to investigate the efficacy and safety of picosecond, neodymium-doped yttrium aluminum garnet laser laser therapy on patients with melasma…
- Trial name
- NCT03040089
- Testing
- PICO+4, Neoquine Cream 2%
- Volunteers
- 40 people
- Sponsor
- CynosureLutronic
Melasma
EFFICACY and TOLERABILITY of TESTED FORMULA VS. HYDROQUINONE 4% in the TREATMENT of FACIAL MELASMA
This study aims at assessing the non-inferiority of tested formula facial serum (2039125 03) versus hydroquinone 4% over 3 months for treatment and then 3 months for maintenance ofwomen subjects presenting facial melasma.
- Trial name
- NCT06787846
- Testing
- Experimental: Group TP, Active Comparator: Group HQ: Hydroquinone 4%
- Where
- Brazil
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Tattoo; Pigmentation, Melasma
Lutronic PicoPlus Exploratory Clinical Trial
This study will evaluate the use of the Lutronic PicoPlus for treatment of dermatological conditions such as unwanted tattoos and benign pigmented lesions.
- Conditions
- Tattoo; Pigmentation, Melasma, Benign Pigmented Lesion
- Trial name
- NCT03415685
- Testing
- PicoPlus laser system
- Where
- 4 sites in United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- CynosureLutronic
Facial Melasma
Efficacy and Safety of a 4% Hydroquinone Cream for the Treatment of Melasma
To assess the ability of a new 4% Hydroquinone formulation (Melanoderm 4% Crema) to reduce melasma on the face, using a split-face randomization design, evaluating the MASI Score from baseline to week 4 and week 8, in both…
- Trial name
- NCT02095990
- Testing
- Hydroquinone
- Where
- Spain
- Volunteers
- 17 people
- Sponsor
- Mesoestetic Pharma Group S.L.